Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Abbott Announces Future of Biowearables at Consumer Electronics Show

This image opens in the lightbox

News provided by

Abbott

06 Jan, 2022, 18:22 GMT

Share this article

Share toX

Share this article

Share toX

- The company announced it's developing a new category of consumer biowearables called Lingo, which is being designed to track key signals in the body – such as glucose, ketones, and lactate – to help people better understand their general health and take action

- Abbott is the first healthcare company to headline the Consumer Electronics Show, with Chairman and CEO Robert Ford presenting alongside scientists and inventors, industry partners, influencers and people who use Abbott health tech

LAS VEGAS, Jan. 6, 2022 /PRNewswire/ -- Making CES history, Abbott (NYSE: ABT) presented a keynote at the most influential tech event in the world, the first healthcare company ever to do so.

Abbott Chairman and Chief Executive Officer Robert B. Ford headlined the event, "Human-Powered Health: Unlocking the Possibility of You."

"Technology gives us the power to digitize, decentralize and democratize healthcare, create a shared language between you and your doctor – and put more control of your health in your hands," Mr. Ford said. "We're creating a future that will bring you and your loved ones care that's more personal and precise. It's happening right now. And its potential is no less than incredible."

Lingo – Speaking Your Body's Unique Language

During the keynote, the company announced it's developing a new category of consumer biowearables called Lingoi. These biowearables are being designed to translate your body's unique language into actionable data to help you track and measure your general health and wellness. The sensor technology is being designed to track key signals in the body such as glucose, ketones and lactate, and could also be used one day to track alcohol levels.

"This will be like having a window into your body," Mr. Ford said. "It's science that you will be able to access any time so you can understand what your body is telling you and what it needs. Our vision is that Lingo will go far beyond today's wearables for consumers to help you proactively manage your health, nutrition and athletic performance."

Lingo extends the Abbott sensing technology platform that Abbott pioneered in 2014 for people with diabetes, allowing people to continuously monitor their glucose levels with a small sensor on the back of the upper arm. Actress and comedian Sherri Shepherd shared live on the CES stage how FreeStyle Libre 2 changed her life, giving her glucose readings, right on her smartphoneii, unique to her body so she can make healthier decisions.

Abbott then built this technology platform to develop a product designed for athletes with the 2020 launch of Libre Sense Glucose Sport Biowearableiii in Europe. Elite athletes, like marathon world record holder Eliud Kipchoge, use this biowearable to optimize how they fuel their bodies for rigorous training. Lingo aims to expand glucose monitoring to people looking to manage their weight, sleep better, improve energy and think clearer.

Abbott is designing Lingo to measure other biomarkers beyond glucose in the future. A ketone biowearable is being developed to track ketones continuously, see how fast you are getting into ketosis, and understand exactly what keeps you there by providing insights on dieting and weight loss. A lactate biowearable is in development to track continuous lactate build up during exercise, which can be used as an indicator of athletic performance.

A Human Focus

Beyond those who demonstrated the human impact of Abbott's sensors, Mr. Ford was joined on stage by people whose lives were impacted by Abbott devices, partners who rallied to provide seamless and safe travel experiences and other visionaries in the industry.

  • Tyrone Morris, a heart failure patient who was given six months to live, shared his story of how he beat the odds thanks to three separate Abbott devices: HeartMate 3iv, CardioMEMSv and an implantable defibrillator. Today, Morris owns a barbecue catering business and food trucks in Humble, Texas, where he specializes in low-sodium recipes.
  • United Airlines' Managing Director of Hospitality & Planning Aaron McMillan and Dr. Patrice Harris, co-founder and CEO of eMed, a digital health company democratizing healthcare through its Digital-Point-of-Care™ platform, described how they came together with Abbott to help people fly confidently and conveniently with BinaxNOW COVID-19 Home Testsvi. United customers can take the proctored tests when traveling and have those results seamlessly confirmed by Abbott's NAVICA app and verified through United's Travel Ready Center.
  • Dr. Fiona Gupta of Mount Sinai Health System in New York highlighted how she uses the NeuroSphere Virtual Clinic, a first-of-its-kind technology in the U.S., that provides people with deep brain stimulation remotely, so physicians can optimize and adjust treatments over cellular or Wi-Fi while Parkinson's and chronic pain patients consult with them from the comfort of their living rooms.
  • The head of the University of Southern California's Center for Body Computing Dr. Leslie Saxon shared her vision of "Lifecare," which addresses everything from preventing sudden deaths to enhancing human performance.
  • Dr. Mary Rodgers, an Abbott virus hunter, shared how a first-of-its-kind network called the Abbott Pandemic Defense Coalition – stretching from Brazil to Senegal to Thailand – is working to identify new viruses and help stop them before they can spread.
  • Dr. Hakim Bouzamondo, head of Nutrition research and development at Abbott, shared how the science behind the microbiome can optimize overall health with personalized nutrition.

Indications and Important Safety Information
FreeStyle Libre 2 system: Failure to use FreeStyle Libre 2 system as instructed in labeling may result in missing a severe low or high glucose event and/or making a treatment decision, resulting in injury. If glucose alarms and readings do not match symptoms or expectations, use a fingerstick value from a blood glucose meter for treatment decisions. Seek medical attention when appropriate or contact Abbott at 855-632-8658 or FreeStyleLibre.us for safety info.

About Abbott
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 109,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com, on LinkedIn at www.linkedin.com/company/abbott-/, on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews.

i The Lingo portfolio of products are under development and are not intended for medical use. They are not intended for use in screening, diagnosis, treatment, cure, mitigation, prevention, or monitoring of diseases. Lingo Portfolio of products are not for sale in the U.S.

ii The FreeStyle Libre 2 app is only compatible with certain mobile devices and operating systems. Please check our website for more information about device compatibility before using the app. Use of the FreeStyle Libre 2 app requires registration with LibreView.

iii The Libre Sense Biosensor is not available in the United States and not intended for medical use.

iv The HeartMate 3 Left Ventricular Assist System is indicated for providing short- and long-term mechanical circulatory support in adult and pediatric patients with advanced refractory left ventricular heart failure and with an appropriate body surface area. Prior to using this device, please review the Instructions for Use at https://www.cardiovascular.abbott/us. Views expressed are the patient's own. 

v The CardioMEMS™ HF System is indicated for wirelessly measuring and monitoring pulmonary artery (PA) pressure and heart rate in New York Heart Association (NYHA) Class III heart failure patients who have been hospitalized for heart failure in the previous year. The hemodynamic data are used by physicians for heart failure management and with the goal of reducing heart failure hospitalizations. Prior to using this device, please review the Instructions for Use at https://www.cardiovascular.abbott/us. Views expressed are the patient's own. 

vi The BinaxNOW™ COVID-19 Ag Card Home Test has received U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA). This product has not been FDA cleared or approved but has been authorized by FDA under an EUA. This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens. This product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of IVDs for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

Related Links

http://www.abbott.com

Modal title

Also from this source

New Clinical Study Data Showcase Long-Term, Sustained Benefits of Abbott's Volt™ PFA System for Patients with AFib

New Clinical Study Data Showcase Long-Term, Sustained Benefits of Abbott's Volt™ PFA System for Patients with AFib

Abbott (NYSE: ABT) has announced new data from its Volt CE Mark Study that show strong safety and efficacy out to 12 months for patients receiving...

Abbott Receives CE Mark for its Volt™ Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms

Abbott Receives CE Mark for its Volt™ Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms

Abbott (NYSE: ABT) today announced it has received CE Mark in Europe for the Volt™ PFA System to treat patients battling atrial fibrillation (AFib)....

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Pharmaceuticals

Pharmaceuticals

Household, Consumer & Cosmetics

Household, Consumer & Cosmetics

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.